Lager et al. base their introduction on the premise that DRF has been shown to improve gastrointestinal tolerance compared to dimethyl fumarate (DMF) in two trials, namely EVOLVE-MS-1 [ 2 ] and EVOLVE-MS-2 [ 3 ]. However, this comparison has …

In acknowledgement of the comment regarding the reference to the EVOLVE-MS-1 study in the introduction: The sentence in the introduction stating “Two phase 3 clinical studies of DRF in patients with MS have demonstrated favorable GI tolerability …

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that results in physical and cognitive disabilities [ 1 ]. The chronic and heterogeneous nature of MS results in a wide array of symptoms and the need …

COVID-19 is a potentially fatal respiratory illness caused by the novel coronavirus SARS-CoV-2, which has developed into the ongoing global pandemic [ 1 , 2 ]. As of June 2022, over one million people in the USA and over six million worldwide have …

Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for the treatment of patients with relapsing forms of multiple sclerosis (MS) [ 1 ]. DRF undergoes esterase cleavage to monomethyl fumarate, the same pharmacologically active …

This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.21318204 .

This article is published with digital features, including a graphic abstract, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.19697629 .

This article is published with digital features, including an infographic, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.19086380 .

This article is published with digital features, including a summary slide and infographic, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.14179409 .

Delayed-release dimethyl fumarate (DMF) is a fumaric acid ester (FAE) approved as an oral therapy for relapsing forms of multiple sclerosis (MS). DMF has been shown to be effective in significantly reducing clinical and radiologic measures of …

Cladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune …

This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.20654583 .

Multiple sclerosis (MS) is characterized by progressive neuroinflammation and neurodegeneration from disease onset that, if left untreated, can result in the accumulation of irreversible neurological disability. Early intervention with …

MS is a chronic demyelinating disorder of the central nervous system that is clasified as an immune-mediated inflammatory disease [ 1 , 2 ]. The clinical course and severity of the disease are variable, but the most common symptoms of the disease …

Relapsing–remitting multiple sclerosis (RRMS) is an immune-mediated, neurodegenerative disease characterized by episodes of relapses followed by periods of remission [ 1 ]. Although episodes of neurologic dysfunction are often followed by periods …

Multiple sclerosis (MS) is a chronic autoimmune demyelinating and neurodegenerative disease of the central nervous system with a wide variety of clinical phenotypes. In spite of the phenotypic classification of MS patients, current data provide …

The absolute and relative number of persons with multiple sclerosis (PwMS) above the age of 55 years is increasing [ 1 ]. Recently published health insurance data from Germany demonstrated an overall increase of MS prevalence and showed that the …